FDA expands J&J’s Rybrevant Faspro label with head and neck cancer approval
The US Food and Drug Administration (FDA) has authorised Johnson & Johnson’s (J&J) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for certain…
06 Nov 2026
MHRA champions patient voices through new policy
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has unveiled a policy to enhance the role of patients and the public in forming drug and medical device regulation. Dubbed…
06 Nov 2026
Armada to combine with Brains Bioceutical in $750m deal
Armada Acquisition has entered a definitive business combination agreement with Brains Bioceutical that values the latter at an implied pre-money equity value of about $750m. Following completion of the merger,…
06 Nov 2026
Alfasigma receives EC’s expanded approval for filgotinib to treat axSpA
Alfasigma has received expanded approval from the European Commission (EC) for Jyseleca (filgotinib) to treat adult patients living with active axial spondyloarthritis (axSpA). The additional indication approval covers radiographic and…
05 Nov 2026
Cordavis to stay in CVS Health after bifurcation of $117bn empire
CVS Health will keep biosimilar subsidiary Cordavis under its umbrella, after the company announced plans to split off its pharmacy chain from its health business. On 4 November, CVS Health…
05 Nov 2026
Big pharma-backed T-Therapeutics snags $133m to bring TCEs to clinic
UK-based biotech T-Therapeutics has netted $133m in a Series B financing round to bring its range of first-in-class T-cell receptor (TCR)-targeting T-cell engager (TCE) therapies for cancer and autoimmune diseases…
05 Nov 2026
Evommune signs $1.1bn licence deal with Hinova for EVO570
Evommune has secured exclusive rights outside Greater China to develop, manufacture and commercialise EVO570, an autoimmune therapy, from Hinova Pharmaceuticals in a licence deal worth up to around $1.1bn. Evommune…